Forte Biosciences
FBRX
50 hedge funds and large institutions have $6.25M invested in Forte Biosciences in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 10 closing their positions.
128% more call options, than puts
Call options by funds: $89K | Put options by funds: $39K
108% more capital invested
Capital invested by funds: $3.01M → $6.25M (+$3.25M)
0.01% less ownership
Funds ownership: 0.06% → 0.06% (-0.01%)
2% less funds holding
Funds holding: 51 → 50 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$267K |
| 2 |
MA
MYDA Advisors
Woodmere,
New York
|
+$175K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$172K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$48.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$191K |
| 2 |
State Street
Boston,
Massachusetts
|
-$191K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$146K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$104K |
| 5 |
Two Sigma Investments
New York
|
-$93.4K |
FBRX Hedge Fund Activity: Q1 2020 in Review
50 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q1 2020, worth a combined $6.25M — up 108% from $3.01M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FBRX and 9 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $267K. The largest seller was Acadian Asset Management, cutting an estimated $191K.
- 50 institutional investors held Forte Biosciences (FBRX) as of Q1 2020, down from 51 in Q4 2019.
- Funds reported $6.25M of Forte Biosciences stock for Q1 2020, up 108% quarter-over-quarter.
- 9 funds opened new Forte Biosciences positions in Q1 2020 and 10 closed out, a net change of -1 holder.
- The largest Forte Biosciences buyer in Q1 2020 was Morgan Stanley, an estimated $267K added.
- The largest Forte Biosciences seller in Q1 2020 was Acadian Asset Management, an estimated $191K sold.
Based on aggregated 13F filings for Q1 2020.